Viamet, Novartis Fund Targeting Metalloenzymes in $200M Deal
Viamet Pharmaceuticals Inc. signed a deal worth more than $200 million with the Novartis Option Fund to discover and develop metalloenzyme inhibitors of interest to the Swiss drugmaker. (BioWorld Today)